Microsulis Medical Ltd will exhibit its Accu2i percutaneous microwave tissue ablation (pMTA) system for the first time at the forthcoming annual European Congress of Radiology in Vienna, Austria. From 4 to 7 March 2011, Microsulis will feature case studies from key centres using the system.
The Accu2i pMTA system, which is cleared for use in Europe, the United States and Canada, combines extreme ease of use with the widest range of clinical applications for rapid, precise coagulation of unwanted tissue masses, whilst avoiding the risks associated with longer, more invasive surgical interventions.
The device is a single high power high frequency 2.45GHz closed water-cooled microwave needle of 1.8mm diameter that can address tissue masses over 5cm in size in just six minutes, and is therefore between 3 to 10 times faster than other systems. Its launch followed two years of extensive clinical use and evaluation in major centres around the world. Clinicians have used the device primarily in the treatment of liver and lung disease.
“Building on the momentum we have experienced in the first few weeks of 2011 with approval by Health Canada and the large order placed by our Italian distributor, MDH, we are looking forward to successfully demonstrating the Accu2i to an extensive range of European radiologists,” commented Stuart McIntyre, CEO of Microsulis.
“Increasing numbers of clinicians around the world are adopting the radically improved performance and ease of use of the Acculis system, moving away from older radiofrequency ablation systems. With the successful use of the Accu2i pMTA system for the treatment of liver and lung disease worldwide, the device has been shown to be very versatile and able to address a wide range of soft tissue targets in the body. Exhibiting at ECR will allow a broader audience to see the new Accu2i pMTA system and appreciate how the system sets a new benchmark, allowing them to treat more patients with more severe disease,” McIntyre added.
